The KLOW Stack: GHK-Cu, KPV, BPC-157 and TB-500 Research Guide
The KLOW Stack is one of the most discussed four-peptide combinations in regenerative research in 2026 — combining GHK-Cu, KPV, BPC-157, and TB-500 to address tissue repair, skin regeneration, and anti-inflammatory signaling through four complementary mechanisms simultaneously. It is an evolution of the well-established Glow Stack, with KPV added as the fourth component to broaden the protocol's anti-inflammatory and mucosal coverage.
What is the KLOW Stack?
KLOW is a four-peptide research blend combining GHK-Cu (glycyl-L-histidyl-L-lysine copper), KPV (lysine-proline-valine), BPC-157 (Body Protection Compound-157), and TB-500 (a synthetic fragment of thymosin beta-4). The standard formulation is an 80mg vial containing GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, and TB-500 10mg — reconstituted with 3ml bacteriostatic water to produce a total blend concentration of approximately 26.7mg/ml.
The name distinguishes it from the similar-sounding Glow Stack (GHK-Cu + BPC-157 + TB-500) and the broader "glow" category of skin peptides. The addition of KPV is what defines KLOW mechanistically — it takes the three-compound Glow trio and adds a targeted anti-inflammatory and mucosal barrier mechanism that the original combination does not have.
The four mechanisms — why each compound is in the stack
GHK-Cu (50mg — the anchor compound). At 50mg, GHK-Cu constitutes the largest component of the KLOW vial by a significant margin. This reflects its foundational role: GHK-Cu activates approximately 31% of human tissue remodeling genes, upregulates collagen and elastin synthesis, modulates TGF-beta to reduce fibrosis, inhibits pro-inflammatory cytokines, stimulates antioxidant enzyme activity, and promotes hair follicle cycling. Its natural plasma concentration declines from approximately 200ng/mL at age 20 to 80ng/mL by age 60 — a decline directly associated with slower wound healing, thinner skin, and reduced hair follicle activity. The 50mg concentration in KLOW reflects its role as the primary structural and gene-activation driver in the stack.
BPC-157 (10mg — vascularization and growth factor signaling). BPC-157 contributes VEGFR2-driven angiogenesis — creating new blood vessel networks that deliver oxygen and nutrients to skin, hair follicle, and connective tissue. Its ERK1/2 pathway activation promotes endothelial cell proliferation and fibroblast activity. Growth hormone receptor upregulation in fibroblasts amplifies the collagen-building response. The anti-inflammatory cytokine reduction from BPC-157 complements both GHK-Cu's cytokine modulation and KPV's melanocortin receptor signaling, creating overlapping but mechanistically distinct anti-inflammatory coverage.
TB-500 (10mg — cellular mobilization and anti-fibrosis). TB-500's G-actin sequestration drives rapid cell migration into repair sites — populating the vascular infrastructure that BPC-157 creates with repair-competent cells. Its amino acid 1-4 segment provides anti-fibrotic effects relevant to scar prevention and normal tissue architecture maintenance. The Wnt/beta-catenin pathway activation confirmed in TB-500 research is directly relevant to the KLOW stack's hair follicle cycling goals, as this pathway governs hair follicle stem cell activation and the anagen growth phase transition.
KPV (10mg — the differentiating addition). KPV (lysine-proline-valine) is a tripeptide derived from the C-terminal sequence of alpha-MSH (alpha-melanocyte stimulating hormone). It binds melanocortin receptors — primarily MC1R and MC3R — to produce direct anti-inflammatory effects including reduction of NF-kB pathway activation, suppression of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), and promotion of intestinal epithelial cell migration for mucosal barrier repair. KPV is the compound that broadens KLOW from a pure skin and tissue repair protocol to one that also covers inflammatory pathway modulation and gut-skin axis research. This is the mechanism the Glow Stack does not have.
Get the GHK-Cu Complete Research Protocol PDF — dosing, reconstitution, Glow and KLOW stacks. Free, instant download.
KLOW vs Glow — what is the difference and which to choose?
The Glow Stack (GHK-Cu + BPC-157 + TB-500) and the KLOW Stack (GHK-Cu + KPV + BPC-157 + TB-500) are not competing protocols — they serve overlapping but distinct research objectives.
For research focused specifically on skin regeneration, collagen synthesis, wound healing, and hair growth — with the primary outcome being structural tissue improvement — the Glow Stack is the more targeted and simpler choice. Three compounds, all working through tissue regeneration mechanisms, with GHK-Cu's gene activation providing the broadest coverage.
For research where anti-inflammatory pathway modulation, mucosal barrier function, gut lining repair, or systemic inflammatory response is a co-primary or secondary outcome alongside skin and tissue repair — KLOW is the more comprehensive choice. KPV's melanocortin receptor mechanism adds coverage that none of the three Glow compounds address, making KLOW more appropriate for research involving inflammatory conditions, post-procedure recovery with a significant inflammatory component, or protocols where the gut-skin axis is a research variable.
Neither is strictly better — they target different research questions. The decision comes down to whether anti-inflammatory and mucosal coverage is relevant to the specific research objective.
Research protocol and dosing
Standard reconstitution: inject 3ml bacteriostatic water slowly down the inside wall of the 80mg KLOW vial. Swirl gently until fully dissolved. Do not shake. The resulting concentration is approximately 26.7mg/ml total blend. Refrigerate at 2–4 degrees C after reconstitution. Use within 28–60 days.
Research dose: 1–2mg (approximately 4–8 units on an insulin syringe) administered subcutaneously. Daily administration is standard. 30-day cycles with a 14-day break are the most commonly used protocol in the research community. Administration site: abdomen, thigh, or lateral hip — the same sites used for GHK-Cu mono-administration. Morning or early afternoon dosing. See the KLOW Blend database entry for full specifications and the interactive dose calculator. For comparison, see the Wolverine Blend (BPC-157 + TB-500 for injury-focused healing) and the Glow Stack Research Guide.
Search trends and research community interest in 2026
The KLOW stack has emerged as one of the more searched peptide combinations in the first half of 2026, driven by growing interest in multi-mechanism skin and recovery protocols and the expanding research community awareness of KPV's anti-inflammatory profile. The comparison between KLOW and Glow has become a common question in peptide research communities — reflecting an audience that is increasingly sophisticated about mechanistic differences between similar-sounding protocols.
Research references
- Sikiric P, et al. (2000). The influence of a novel pentadecapeptide, BPC 157 — PubMed
- Malinda KM, et al. (1999). Thymosin beta4 accelerates wound healing — PubMed
Research sourcing: For research-grade GHK-Cu, KPV, BPC-157, and TB-500 with third-party COA documentation, Peptide Hub recommends Amino Club (partner code: PEPTIDEHUB). Affiliate link — we earn a commission at no cost to you.